Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

The letter specifies violations at its Halol facility, with regards to manufacturing of goods.

FPJ Web DeskUpdated: Friday, December 16, 2022, 07:35 PM IST
article-image
Representational image |

Through an exchange filing, Revital maker Sun Pharma has informed that it has received a warning letter from the US Food and Drug Administration.

The letter specifies violations at its Halol facility, with regards to manufacturing of goods, and contents of the letter will be released to the public soon.

RECENT STORIES

Gautam Adani Joins Puri's Shree Jagannath Rath Yatra 2025, Adani Group Launches Massive 'Prasad...

Gautam Adani Joins Puri's Shree Jagannath Rath Yatra 2025, Adani Group Launches Massive 'Prasad...

LG Eyes Space Industry Entry, Unveils Ambitious Lunar Landing Goal by 2032

LG Eyes Space Industry Entry, Unveils Ambitious Lunar Landing Goal by 2032

Meesho Receives Shareholder Approval To Launch IPO; $500 Million In Fresh Capital

Meesho Receives Shareholder Approval To Launch IPO; $500 Million In Fresh Capital

India & Bangladesh Conflict: India Bans Jute Imports & Woven Fabrics

India & Bangladesh Conflict: India Bans Jute Imports & Woven Fabrics

Can’t Wait For iPhone 17? These 5 Flagship Smartphones Launching Before September Might Be Better...

Can’t Wait For iPhone 17? These 5 Flagship Smartphones Launching Before September Might Be Better...